恒瑞医药：SHR-4712注射液获批开展临床试验

Core Viewpoint - Heng Rui Medicine announced that its subsidiaries, Guangdong Heng Rui Medicine Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SHR-4712 injection, which will soon commence [1] Group 1: Product Development - SHR-4712 injection is a self-developed Class 1 therapeutic biological product intended for the treatment of advanced solid tumors [1] - The drug is designed to specifically bind to tumor-associated antigens and activate immune cells in the tumor microenvironment, exerting targeted anti-tumor effects [1] - The total research and development investment for the SHR-4712 injection project has reached approximately 24.92 million yuan [1]